In this study-level meta-analysis of randomized controlled trials (RCTs) evaluating the effect of early aortic valve replacement (AVR) versus clinical surveillance (CS) in patients with asymptomatic severe aortic stenosis (AS), four RCTs were identified and included for analysis: AVATAR, RECOVERY, EARLY TAVR, EVOLVED.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Aortic Valve
January 16, 2025
January 9, 2025
The treatment of aortic valve disease has evolved, and it is expected that TAVR will be available to most patients in the next few years. However, TAVR with a bioprosthesis will continue to be indicated and used. It is well documented that the use of a small valve, particularly in young patients, presents clinical challenges.
December 27, 2024
This study investigated the impact of patient-prosthesis mismatch (PPM) on long-term mortality and reoperation rates over a 15-year follow-up in patients who underwent biologic aortic valve replacement.
December 19, 2024
Surgeons at the West Virginia University Heart and Vascular Institute performed the world’s first combined robotic aortic valve replacement (AVR) and coronary artery bypass grafting (CABG) through a single small incision. The groundbreaking procedure, led by Dr.
December 12, 2024
This article examines the results of the COMMENCE trial, which evaluated the safety and effectiveness of surgical aortic valve replacement using RESILIA tissue valves during a five-year period in patients with native bicuspid aortic valves, comparing outcomes with those of patients with tricuspid aortic valves.
December 5, 2024
Development of myocardial fibrosis in patients with aortic stenosis precedes left ventricular decompensation and is associated with an adverse long-term prognosis.
November 26, 2024
Neurohormonal modulation and afterload reduction are essential for treating heart failure with reduced ejection fraction (HFrEF). In HFrEF patients with concomitant moderate aortic stenosis (AS), therapy with transcatheter aortic valve replacement (TAVR) may be complementary to guideline-directed medical therapy (GDMT).
November 26, 2024
This study compared outcomes between patients undergoing valve-in-valve transcatheter aortic valve replacement (ViV TAVR) and redo surgical aortic valve replacement (redo SAVR) using a retrospective analysis of institutional databases, which included data from 2013 to 2022 for TAVR and 2011 to 2022 for SAVR.
November 26, 2024
The EARLY TAVR trial investigators randomly assigned patients with asymptomatic severe aortic stenosis to undergo either early transfemoral transcatheter aortic valve replacement (TAVR) or clinical surveillance. The primary end point was a composite of death, stroke, or unplanned hospitalization for cardiovascular causes.
November 7, 2024
Aortic stenosis is the most prevalent valvular heart condition necessitating surgical intervention, with full sternotomy (FS) traditionally being the standard approach for surgical aortic valve replacement (SAVR).